November 24, 2016 - By Peter Erickson
7,500 shares of Nxstage Medical Inc were unloaded by Jeffrey Burbank, the company’s Chief Executive Officer. The unloaded shares are valued at close to $180,075 which has been calculated on the basis of the average transactions stock price ($24.0 for share). In the last month, he also unloaded 7,500 shares worth about $191,325 USD. Currently, Jeffrey Burbank has ownership of a total of 897,616 shares or 1.35% of the Company’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding). A document ready for use online here unveiled this sale activity. It was unveiled on 23-11-2016 and filled with U.S. SEC.
Out of 6 analysts covering NxStage Medical (NASDAQ:NXTM), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. $30 is the highest target while $14 is the lowest. The $23.10 average target is -8.48% below today’s ($25.24) stock price. NxStage Medical has been the topic of 7 analyst reports since November 4, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Canaccord Genuity on Tuesday, August 2. Sterne Agee CRT initiated the shares of NXTM in a report on Friday, December 11 with “Buy” rating. Piper Jaffray reinitiated the shares of NXTM in a report on Thursday, March 31 with “Overweight” rating. Northland Capital upgraded NxStage Medical, Inc. (NASDAQ:NXTM) on Tuesday, June 28 to “Outperform” rating. The firm has “Buy” rating given on Friday, December 18 by BTIG Research.
Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.23, from 0.97 in 2016Q1. The ratio is positive, as 22 funds sold all NxStage Medical, Inc. shares owned while 45 reduced positions. 26 funds bought stakes while 39 increased positions. They now own 61.50 million shares or 4.11% more from 59.07 million shares in 2016Q1.
Invesco accumulated 2.46M shares or 0.02% of the stock. Consonance Mngmt Limited Partnership last reported 2.56% of its portfolio in the stock. Panagora Asset Mngmt accumulated 11,371 shares or 0% of the stock. Moreover, Portolan Cap Mgmt Ltd has 0.67% invested in NxStage Medical, Inc. (NASDAQ:NXTM) for 215,810 shares. Great West Life Assurance Company Can, a Manitoba – Canada-based fund reported 8,228 shares. Clinton Grp Inc Inc, a New York-based fund reported 39,114 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 1,205 shares or 0% of its portfolio. State Of New Jersey Common Pension Fund D holds 0.01% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM) for 76,700 shares. Menta Cap Ltd Liability Co, a California-based fund reported 37,180 shares. Wells Fargo And Mn last reported 0.01% of its portfolio in the stock. Geode Ltd Liability last reported 0.01% of its portfolio in the stock. Alliancebernstein Ltd Partnership reported 109,310 shares or 0% of all its holdings. Fmr Limited Liability Company accumulated 0.02% or 7.54M shares. Prudential Financial Inc last reported 501,096 shares in the company. Ny State Common Retirement Fund holds 81,881 shares or 0% of its portfolio.
Insider Transactions: Since September 12, 2016, the stock had 0 buys, and 8 selling transactions for $1.41 million net activity. 7,500 shares were sold by Burbank Jeffrey H, worth $180,075. Turk Joseph E Jr also sold $25,970 worth of NxStage Medical, Inc. (NASDAQ:NXTM) on Thursday, November 17. Giannini Daniel A sold $167,416 worth of stock or 6,449 shares. On Monday, September 12 the insider MOORE CRAIG W sold $69,930. Another trade for 3,000 shares valued at $76,530 was made by Swan Winifred L on Tuesday, November 22. TOWSE MATTHEW W sold $112,789 worth of stock or 4,300 shares.
The stock increased 3.06% or $0.75 during the last trading session, hitting $25.24. About 539,142 shares traded hands or 35.85% up from the average. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 59.24% since April 22, 2016 and is uptrending. It has outperformed by 53.91% the S&P500.
NxStage Medical, Inc. is a medical technology company. The company has a market cap of $1.55 billion. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. It currently has negative earnings. The Firm operates through three divisions: System One, In-Center and Services.
According to Zacks Investment Research, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.”
Analysts await NxStage Medical, Inc. (NASDAQ:NXTM) to report earnings on February, 8. They expect $-0.02 earnings per share, up 50.00% or $0.02 from last year’s $-0.04 per share.
More recent NxStage Medical, Inc. (NASDAQ:NXTM) news were published by: Fool.com which released: “Here’s Why NxStage Medical, Inc.’s Stock Is Popping Today” on November 03, 2016. Also Fool.com published the news titled: “Home and Critical Care Drive NxStage Medical, Inc. Q2 Improvement” on August 04, 2016. Fool.com‘s news article titled: “Why NxStage Medical, Inc. Guided Lower Today” with publication date: February 10, 2016 was also an interesting one.
NxStage Medical, Inc., incorporated on October 20, 1998, is a medical technology company. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. The Firm operates through three divisions: System One, In-Center and Services. The Firm offers its services and products to various markets, such as home, critical care and in-center. The Company’s primary product, the System One, delivers the therapeutic flexibility and clinical benefits associated with dialysis machines that can be used by healthcare professionals and trained lay users alike in various settings, including patient homes, as well as traditional care settings, such as hospitals and dialysis centers. The Firm operates NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.